In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Bio-Path Holdings, Inc.. Trade Record

NASDAQ:BPTH Bio-Path Holdings, Inc. stock gains 16.55% Exit Oct 18, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart BPTH Oct 6, 2017, priceSeries
About Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2, which is in Phase I clinical trial for the treatment of lymphoma. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Trade Information
Trade Type
LONG
ReliabilityScore™
77.78
Entry Date
Oct 6, 2017
Entry Price
77.00
Sell Date
Oct 18, 2017
Sell Price
89.75
Net Gain
16.55%
Hold Time
8 Trading Days